CCCC FY 2020 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$239M

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+55.3% YoY

Gross Profit

-$45M-136.3% margin

Operating Income

-$60M-182.1% margin

Net Income

-$66M-199.8% margin

EPS (Diluted)

$-1.54

Cash Flow

Operating Cash Flow

-$67M

Free Cash Flow

-$68M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$400M

Total Liabilities

$119M

Stockholders' Equity

$281M

Cash & Equivalents

$182M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$21M	+55.3%
Gross Profit	-$45M	$21M	-311.6%
Operating Income	-$60M	-$35M	-70.5%
Net Income	-$66M	-$34M	-94.5%